AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Neurosciencenews

Published November 9, 2026

Psychedelics Linked to Lower Anxiety and Depression in Young Adults

Read the full story at Neurosciencenews

An epidemiological investigation from Durham University reveals that the mental health benefits linked to classic psychedelics , such as psilocybin and.

Post on X

Share this story

Surfaced by 5 Google Alerts

Psychedelics
Ketamine
LSD
Magic mushrooms
MDMA